Chemotherapy News and Research

Latest Chemotherapy News and Research

Parents are concerned about the overuse of prescription medications with their children: Survey

A new nationwide survey released today reveals that just 12 percent of parents with children under the age of 18 have spoken to their child's doctor about complementary and integrative approaches to medicine, yet nearly 90 percent say they want to know more.

19 Oct 2009

Rituxan's sBLA receives a Complete Response from the FDA

Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.

19 Oct 2009

New chromosomal abnormality in acute lymphoblastic leukemia

Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.

19 Oct 2009

FDA grants marketing approval for Elitek

Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.

19 Oct 2009

Recently approved Gleevec drug for cancer treatment

Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual meeting of the American College of Rheumatology on October 18 in Philadelphia.

19 Oct 2009

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

19 Oct 2009

China's SFDA approves Celsion’s global Phase III ThermoDox HEAT trial for treating liver cancer

Celsion Corporation announced today that it has received official approval from China’s State Food and Drug Administration (“SFDA”) for its Clinical Trial Application for ThermoDox that permits Celsion to include Chinese clinical trial sites in its Phase III ThermoDox HEAT trial for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC).

15 Oct 2009

Access Pharmaceuticals' update on its European commercial launch of Mugard

ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

15 Oct 2009

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

HTDS - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

15 Oct 2009

Genes to determine which rectal cancer patient can avoid surgical procedure for treatment

A set of 87 genes one day may be used to routinely determine which patients can be successfully treated for advanced rectal cancer without undergoing a surgical procedure, researchers announced at the 2009 Clinical Congress of the American College of Surgeons.

15 Oct 2009

Decision Resources forecasts biosimilar insulins and insulin analogues to erode $6.1 billion in brand sales

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1 billion in brand sales in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018, saving healthcare systems $3.8 billion in the process.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

A genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure, according to a new study reported at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Online medical journal to be launched

Two Johns Hopkins Children's Center researchers have assembled a 25-member editorial board of international experts to launch a quarterly online medical journal devoted to original research and commentary on the use of computer automation in the day-to-day practice of medicine.

15 Oct 2009

Institute of Medicine elects two new members from St. Jude Children's Research Hospital

Michael Kastan, M.D., Ph.D., and Mary Relling, Pharm.D., of St. Jude Children's Research Hospital, have been elected to the Institute of Medicine (IOM), a prestigious branch of the National Academy of Sciences.

15 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Researchers develop magneto-nano sensor chip to detect cancer

Searching for biomarkers that can warn of diseases such as cancer while they are still in their earliest stage is likely to become far easier thanks to an innovative biosensor chip developed by Stanford University researchers.

14 Oct 2009

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Mention the words "bubble boy" and many will recall David Vetter, the kid with big eyes and a thick thatch of dark hair who died 25 years ago after spending almost the entire 12 years of his life in a germ-free, plastic bubble. David was born with severe combined immune deficiency, or SCID, a condition that robbed him of an immune system.

14 Oct 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Parents are concerned about the overuse of prescription medications with their children: Survey

Rituxan's sBLA receives a Complete Response from the FDA

New chromosomal abnormality in acute lymphoblastic leukemia

FDA grants marketing approval for Elitek

Recently approved Gleevec drug for cancer treatment

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

China's SFDA approves Celsion’s global Phase III ThermoDox HEAT trial for treating liver cancer

Access Pharmaceuticals' update on its European commercial launch of Mugard

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

Genes to determine which rectal cancer patient can avoid surgical procedure for treatment

Decision Resources forecasts biosimilar insulins and insulin analogues to erode $6.1 billion in brand sales

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

Online medical journal to be launched

Institute of Medicine elects two new members from St. Jude Children's Research Hospital

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Breakthrough in pancreatic cancer treatment

Researchers develop magneto-nano sensor chip to detect cancer

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Cancer Research - Second Edition eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in